OMED Health® Launches New Gastrointestinal Treatments and Services Through Personalized Health Plans
Published on: 15 Jul 2025
- OMED Health Plans build on proprietary OMED Health Breath Analyzer to include clinician-led care pathways, personalized treatments, and clinical consultations
- Expanded high-value end-to-end solution positions business for rapid growth in multi-billion dollar functional GI market
Cambridge, UK, July 15, 2025: OMED Health® (“OMED”), a UK-based business pioneering non-invasive breath analysis for gut health and part of Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the launch of OMED Health Plans1, personalized treatments and services to help patients gain control of their functional gastrointestinal (GI) conditions, a problem that affects over one billion people worldwide.
OMED Health Plans, available first in Great Britain, include the diagnosis of Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO) through at-home breath testing and substrate tests using the proprietary OMED Health Breath Analyzer, supporting the push to move care from hospitals to communities; clinician-led care pathways including nutritional protocols such as FODMAP and therapeutic interventions; and 1:1 clinical consultation for ongoing expert support. Initially the Plans will be made available through healthcare providers, who will leverage the platform to offer efficient non-invasive GI diagnostics alongside targeted treatment to reduce delivery costs and improve patient outcomes, and to consumers.
“Digestive health is one of the largest untapped opportunities in consumer-facing diagnostics and chronic disease management,” said Billy Boyle, CEO and Co-founder of Owlstone Medical. “Through the expanded OMED offering, patients with functional GI conditions will for the first time be able to access end-to-end, clinician-led, and evidence-based treatment plans utilizing longitudinal breath monitoring, optimized specifically for them based on their breath profiles.”
Feedback from participants in pilot programs has been very positive, with many citing significantly improved digestive health following diagnosis of SIBO or IMO using the OMED Breath Analyzer and subsequent treatment and follow-up monitoring.
“Owlstone is building a category-defining platform through OMED Health at the intersection of diagnostics, digital health, therapeutics, and personalized care,” added Boyle. “With recurring revenue potential, robust unit economics, and a vast addressable market, OMED is well positioned to address a major gap in chronic GI care, enabling rapid growth by providing effective, evidence-based GI care at scale. Beyond the significant opportunity in Great Britain, there is large upside potential through expansion to other markets through strategic partnerships and licensing.”
ENDS
Notes to Editors:
For more information please contact:
Dr Ben Rutter, Zyme Communications
ben.rutter@zymecommications.com
+44 (0) 7920-770935
To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.
About Functional Gastrointestinal Disease:
Functional gut disorders such as IBS, Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and food intolerances affect up to 1 in 8 people globally1. In the UK alone 17% of adults have IBS or another form of GI disease2, or almost 9 million people, many of whom have SIBO. When diagnosed via a breath test, the effectiveness of therapeutics for SIBO such as Rifaximin improves from 40% to over 70%3. Unfortunately, while there are many potential causes, symptoms can be non-specific and so many suffer for years without a clear resolution, impacting every aspect of normal life at home and at work. Overall annual healthcare expenditures for gastrointestinal disease total $136 billion – more than that for heart disease, trauma, or mental health4. As a result, the global digestive health market is projected to reach approximately $104 billion USD by 2032, growing at a compound annual growth rate CAGR of 8.2%5.
- https://gutscharity.org.uk/advice-and-information/conditions/irritable-bowel-syndrome/
- https://www.bjmp.org/content/irritable-bowel-syndrome-primary-care-physicians
- https://journals.lww.com/ajg/Fulltext/2019/12000/Lactulose_Breath_Testing_as_a_Predictor_of.14.aspx
- https://www.jwatch.org/na47723/2018/10/23/burden-and-costs-gastrointestinal-disease-us
- https://www.pharmiweb.com/press-release/2024-05-16/digestive-health-market-set-for-82-cagr-growth-through-2032-highlights-new-product-innovations#:~:text=The%20global%20digestive%20health%20market%20is%20projected%20to%20reach%20USD,of%20the%20revenue%20in%202022
About OMED Health (https://omedhealth.com):
OMED Health is the patient-facing brand of Owlstone Medical that offers patients and GI experts access to breath-based analysis, point-of-care devices, therapeutics and clinical support for digestive disease. The core of the offering is the proprietary OMED Health Breath Analyzer, which measures gases derived from microbiome fermentation in exhaled breath. The multi-use handheld device allows routine monitoring anytime, anywhere, with no incremental cost per measurement, and the associated app allows for regular tracking of diet and lifestyle factors. Now expanded to include doctor-led care supported by OMED’s own in-house clinicians, and Quality Care Commission certified, the platform helps users and healthcare providers make data-driven decisions, improving outcomes and reducing time to treatment so that patients and their doctors can find the problem and fix the problem.
About Owlstone Medical (www.owlstonemedical.com):
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®, a unique platform capable of both biomarker discovery and use in routine clinical testing.
The platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial-scale Breath Biopsy Laboratory located in Cambridge, U.K., and the Breath Biopsy VOC Atlas, the most extensive catalogue of identified volatile organic compounds (VOCs) commonly found on breath. The Company’s technology is protected by over 160 granted and pending patents and has been used in more 100 research papers.
Owlstone Medical’s Research Products and Services are being deployed at over 100 sites around the world with large pharmaceutical companies including AstraZeneca, Actelion (a J&J company), GlaxoSmithKline, and leading academic institutions. Projects are supported by Breath Biopsy OMNI®, the most advanced solution for reliable end-to-end global breath VOC analysis, which is helping researchers advance biomarker discovery and disease research and maximizing the chances of finding clinically relevant breath biomarkers.
The Company has a portfolio of Breath Biopsy tests in development for the early detection of lung cancer and liver disease, both areas of high unmet clinical need that represent multi-billion dollar market opportunities. In digestive health, under the OMED Health brand, clinical tests for Small Intestinal Bacterial Overgrowth and carbohydrate malabsorption are on market in the U.K., and a handheld device and app for longitudinal monitoring of digestive health is in development.
What is Breath Biopsy® (https://www.owlstonemedical.com/science-technology/breath-biopsy/):
Breath Biopsy represents an entirely new way to determine the chemical makeup of breath by measuring volatile organic compounds (VOCs), gaseous molecules that can be sampled quickly and non-invasively. VOCs originate from all parts of the body as the end product of metabolic processes, making Breath Biopsy applicable to a wide range of diseases including lung cancer, liver disease, and digestive disease. The nature of Breath Biopsy therefore makes it perfectly suited to addressing two of the major challenges of healthcare today: early detection of disease and precision medicine.